A US Case Series of Acute Encephalopathy with Biphasic Seizures and Restricted Diffusion (AESD)
Liz Ballinger1, Ryan Kammeyer2, Andrew Silverman3, Dana Harrar4, Jonathan Santoro5, Catherine Otten1, Varun Kannan6, Hanna Retallack7, Mark Wainwright8, Jennifer Yang9, Keith Van Haren10, Thomas Rossor11, Kristen Fisher12
1Seattle Children's Hospital, 2Childrens Hospital Colorado, 3Weill Cornell Medical College, 4Children's National Hospital, 5Department of Neurology, Children's Hospital Los Angeles, 6Emory University, 7Childrens Hospital of Philadelphia, 8Division of Neurology Seattle Childrens Hospital, 9Rady Childrens Hospital/UCSD, 10Stanford Univ Neurology, 11Guy's and St. Thomas' NHS Foundation Trust, 12Baylor College of Medicine
Objective:
To understand clinical presentation, interventions, and outcomes among US children diagnosed with acute encephalopathy with biphasic seizures and late restricted diffusion (AESD).
Background:
AESD is a rare but severe neurologic condition for which epidemiologic and management data remain limited. Here we report the largest US case series to date.
Design/Methods:
We conducted a retrospective multicenter case series of children diagnosed with AESD with longitudinal follow-up. Inclusion/diagnostic criteria included diffusion restriction in subcortical white matter, fever, and encephalopathy (Sakuma et al 2024).
Results:
Twenty-five cases (14 female; median age 21 months, range 2-153) from 9 US hospitals are presented. Seventeen (68%) had no significant past medical history; 8 (32%) had a history of seizure or developmental delay. Of the 16 patients with imaging available from day 1-2 of fever onset, 6 (37.5%) did not show emergence of diffusion restriction until after day 3. Seizures were seen in all but one patient, with status epilepticus in 18 (72%) and a biphasic course of seizures in 18 (72%). The median AESD severity score (Tada et al 2015) was 5 (1-7). A triggering infection was identified in 19 patients (76%), with all but one being viral. Seventeen (68%) patients had systemic complications including transaminitis, respiratory failure, shock, acidosis, thrombocytopenia, and coagulopathy. Twenty-three patients (92%) received acute phase immunomodulatory treatments, with methylprednisolone in 22 patients (88%) and intravenous immunoglobulin (IVIg) in 18 (72%). Eight patients (32%) received escalating immunotherapy including anakinra, tocilizumab, and plasmapheresis. At discharge 17 of 23 patients with available data (73.9%) had moderate disability (mRS ≥3).
MRS obtained at discharge, 6 month follow up, and most recent follow up was not predicted by age at presentation, AESD risk score, or immunotherapy regimen.
Conclusions:
Despite aggressive multimodal therapy, AESD carried a high morbidity rate in this cohort of predominantly young and previously healthy children.
Generative AI Usage
No, did not use generative AI in the drafting or editing in this abstract.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.